Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00233519
Status:
COMPLETED
Last Update Posted:
2012-06-25
First Post:
2005-10-03
Brief Title:
Effects of SomatoKine IplexRecombinant Human Insulin-like Growth Factor-1Recombinant Human Insulin-like Growth Factor-binding Protein-3 rhIGF-IrhIGFBP-3 in Myotonic Dystrophy Type 1 DM1
Sponsor:
University of Rochester
Organization:
University of Rochester
Study Overview
Official Title:
Effects of SomatoKine Iplex rhIGF-IrhIGFBP-3 in Myotonic Dystrophy Type 1 DM1
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to investigate the safety and feasibility of daily subcutaneous injections of recombinant IGF1 complexed with IGF binding protein 3 SomatoKine-INSMED as a treatment for muscle wasting and weakness in myotonic dystrophy type 1
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None